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Strengths and limitations of this study
 ► This will be the first network meta-analysis (NMA) 
to produce comprehensive summaries of the rela-
tive reproductive morbidity of treatment methods for 
cervical preinvasive and early invasive disease.
 ► We will use state-of-the-art methods for combining 
randomised and non-randomised studies in an NMA.
 ► Risk of bias will be evaluated at both study and out-
come level.
 ► One possible limitation of this review is that we ex-
pect to find mainly retrospective cohort studies at 
high risk of recall, selection and publication bias.
AbStrACt
Introduction There are several local treatment methods 
for cervical intraepithelial neoplasia that remove or ablate 
a cone-shaped part of the uterine cervix. There is evidence 
to suggest that these increase the risk of preterm birth 
(PTB) and that this is higher for techniques that remove 
larger parts of the cervix, although the data are conflicting. 
We present a protocol for a systematic review and network 
meta-analysis (NMA) that will update the evidence and 
compare all treatments in terms of fertility and pregnancy 
complications.
Methods and analysis We will search electronic 
databases (CENTRAL, MEDLINE, EMBASE) from inception 
till October 2019, in order to identify randomised controlled 
trials (RCTs) and cohort studies comparing the fertility 
and pregnancy outcomes among different excisional 
and ablative treatment techniques and/or to untreated 
controls. The primary outcome will be PTB (<37 weeks). 
Secondary outcomes will include severe or extreme 
PTB, prelabour rupture of membranes, low birth weight 
(<2500 g), neonatal intensive care unit admission, 
perinatal mortality, total pregnancy rates, first and second 
trimester miscarriage. We will search for published and 
unpublished studies in electronic databases, trial registries 
and we will hand-search references of published papers. 
We will assess the risk of bias in RCTs and cohort studies 
using tools developed by the Cochrane collaboration. 
Two investigators will independently assess the eligibility, 
abstract the data and assess the risk of bias of the 
identified studies. For each outcome, we will perform a 
meta-analysis for each treatment comparison and an 
NMA once the transitivity assumption holds, using the OR 
for dichotomous data. We will use CINeMA (Confidence 
in Network meta-analysis) to assess the quality of the 
evidence for the primary outcome.
Ethics and dissemination Ethical approval is not 
required. Results will be disseminated to academic 
beneficiaries, medical practitioners, patients and the 
public.
PrOSPErO registration number CRD42018115495
IntrOduCtIOn
The introduction of systematic call and recall 
screening programmes in the UK has resulted 
in a profound decrease in the incidence and 
mortality from cervical cancer, as preinvasive 
precursors (cervical intraepithelial neoplasia; 
CIN) can be detected by the screening 
programme and treated.1 In England alone, 
3.6 million women aged 25–64 years attended 
for screening in 2013–2014 and over 23 800 
treatment procedures were carried out.2
Local conservative treatment for cervical 
preinvasive and early invasive disease removes 
or ablates a cone-shaped part of the cervix 
containing the precancerous cells. The choice 
of technique varies within the UK, across 
Europe and beyond. In some countries, knife 
excision (cold knife conisation; CKC) is still 
regularly performed; in others, laser abla-
tion or laser conisation with the laser beam 
is common practice. In the UK, large loop 
excision of the transformation zone (LLETZ) 
is the preferred treatment, with some units 
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offering alternative techniques more frequently than 
others. This preference is because LLETZ is quick, easy 
to do and of low cost.
The mean age of women undergoing CIN treatment 
is similar to the age of women having their first child. 
Although, previously, complications from treatment 
were thought to be relatively mild and uncommon, an 
increasing body of retrospective observational studies and 
meta-analyses suggested that treatment, particularly exci-
sion, adversely affects future reproduction and the risk of 
prematurity.3–8 It has been suggested that the frequency 
and severity of the observed adverse events is higher for 
the more radical techniques and with increasing cone 
depth.4 7 9–14 Preterm birth (PTB) is a major cause of 
neonatal death and disability and represents an enormous 
cost to the health services and the society in general.
Although all treatment techniques are highly effec-
tive in preventing recurrent precancerous disease and 
future invasion,15 some of the data on the risk of repro-
ductive morbidity for the treatment methods has been 
conflicting3 5 7 10 16–18 and their comparative reproductive 
morbidity remains unclear. With some authors raising 
concerns that the progressive reduction in the radicality 
of treatment has led to increased risk of future post-treat-
ment invasive disease,19 20 and others advocating the move 
to less radical techniques, such as laser ablation (LA), for 
the prevention of treatment-associated adverse obstetric 
outcomes, such as PTB or perinatal mortality,4 21 high-
quality synthesis of the current evidence base is an urgent 
unmet need. Given the premalignant nature of the condi-
tion, a randomised controlled trial (RCT) comparing the 
various treatment technique to no treatment will never 
be conducted.
The quantification of the comparative reproductive 
morbidity of different treatment techniques and cone 
lengths has become a women’s health priority. This 
requires high-quality synthesis of the evidence in compre-
hensive summaries that will become available for effec-
tive patient counselling at colposcopy and antenatal 
clinics for patients, clinicians and policymakers. A clin-
ical ranking of treatments with regards to the risk of PTB 
may allow the quantification of risk and the detection of 
women at high risk of PTB that would benefit from inten-
sive surveillance antenatally, while minimising the unnec-
essary interventions for those at lower risk.
The key methodological vehicle to synthesise evidence 
is systematic reviews and their quantitative component, 
meta-analysis. Network meta-analysis (NMA) is an exten-
sion of pairwise meta-analysis, which can be used to 
estimate the relative effectiveness of several competing 
treatments. An NMA has never been used before to assess 
the comparative efficacy and harms of the different treat-
ment techniques in this field. For every treatment compar-
ison NMA synthesises both direct evidence (ie, coming 
from studies comparing head-to-head the treatments of 
interest) and indirect evidence (ie, coming from studies 
comparing the treatments of interest via an intermediate 
common comparator).22–25 In addition, NMA allows the 
estimation of relative effects between all available treat-
ments, can lead to an increased precision as compared 
with the pairwise meta-analysis and provides a ranking 
of the available competing treatments. The potential of 
NMA has been recognised by the National Institute of 
Clinical Excellence26 and several international Health 
Technology Assessment agencies.27 28
The objective of this systematic review and NMA is to 
update the evidence and to compare the various local 
treatment methods to manage CIN in terms of fertility, 
early (<24 weeks of gestation) and late (>24 weeks) preg-
nancy complications. This is part of the CIRCLE project 
(Cervical Cancer Incidence, CIN Recurrence and Repro-
duction after Local Excision), which aims to generate a 
clinically useful raking of alternative options for treatment 
of CIN according to their efficacy (risk of preinvasive and 
invasive recurrence), morbidity and cost-effectiveness.
MEthOdS And AnAlySIS
This protocol complies with the Preferred Reporting 
Items for Systematic Review and Meta-Analysis Proto-
cols (online supplementary file 1).29 Any changes in this 
protocol will be recorded in an updated version of the 
PROSPERO registration.
Criteria for considering studies for this review
Types of participants
We will include women of all ages with a prior history of 
local surgical treatment for CIN or microinvasive early 
cervical cancer (stage IA1). Their status can be confirmed 
with histological or cytological diagnosis and irrespective 
of the grade of the treated lesion for both squamous and 
glandular intraepithelial neoplasia. Studies recruiting 
solely women at high risk of PTB (such as previous history 
of PTB) or studies including only patients treated during 
pregnancy will be excluded.
Types of interventions
We aim to compare nine different excisional or ablative 
techniques used for conservative treatment for CIN. The 
excisional techniques include CKC; laser conisation; 
needle excision of the transformation zone, also known as 
straight wire excision of the transformation zone; LLETZ, 
also known as loop electrosurgical excisional procedure; 
Fischer cone biopsy excision. The ablative techniques 
include radical point diathermy; cryotherapy; cold coagu-
lation; LA. We will include studies comparing any of these 
treatments with each other or with no treatment. Figure 1 
shows a network example of all possible comparisons 
between eligible interventions for the primary analysis. If 
the specific treatment technique is not specified, these 
will be grouped under the broader categories excision or 
ablation.
Outcome measures
Primary outcome
1. PTB, defined as <37 weeks of gestation.
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Figure 1 Network of possible pairwise comparisons between eligible treatment methods. CC,cold coagulation; CKC, 
cold knife conisation; CT, cryotherapy; FCBE, Fischer conebiopsy excision; LA, laser ablation; LC, laser conisation; LLETZ, 
large loopexcision of the transformation zone, also known as LEEP, loop electrosurgicalexcisional procedure; NETZ, 
needle excision of the transformation, also knownas SWETZ, straight wire excision of the transformation zone; RD, radical 
pointdiathermy.
Secondary outcomes
1. Spontaneous PTB, defined as <37 weeks of gestation.
2. Severe PTB, defined as <32/34 weeks of gestation.
3. Extreme PTB, defined as <28/30 weeks of gestation.
4. Prelabour rupture of membranes defined as mem-
brane rupture before the onset of labour.
5. Low birth weight, defined as infant born weighing 
<2500 g (late neonatal obstetric outcome).
6. Neonatal intensive care unit admission.
7. Perinatal mortality, defined as the number of still-
births and neonatal deaths occurring within 28 days 
after birth.
8. Total pregnancy rate, defined as any pregnancy oc-
curring from CIN treatment till study completion 
irrespective of outcome (miscarriage, ectopic, mo-
lar pregnancy, termination of pregnancy, live birth, 
stillbirth).
9. Rates of women requiring >12 months to conceive.
10. First trimester miscarriage, defined as miscarriage at 
<12 weeks of gestation.
11. Second trimester miscarriage, defined as miscarriage 
between 12 and 24 weeks of gestation.
Outcomes and their classification into primary or 
secondary were decided after clinical experts’ opinion. 
Total pregnancy rate will be recorded for the whole study 
period and/or prespecified intervals, if data are available.
Types of studies
We will include RCTs, quasi-RCTs and cohort studies 
comparing fertility and early (<24 weeks of gestation) 
or late (>24 weeks of gestation) pregnancy outcomes 
among surgical techniques and those that compare to 
no treatment. Studies that do not perform a compar-
ison between treatments (ie, ‘single-arm studies’) will 
be excluded. Studies that compared a treatment with an 
untreated group will be included irrespective of the type 
of the untreated group (eg, studies that used data from 
untreated women from the general population; studies 
that used self-matching, ie, including women with preg-
nancies before and after treatment; studies that used 
data from women with a history of abnormal cytology/
HPV infection/untreated CIN). There will be no time or 
language restriction.
Information sources and search strategy
An experienced librarian will search The Cochrane Gynae-
cological Cancer Specialised Register; Cochrane Central 
Register of Controlled Trials (CENTRAL); MEDLINE; 
and EMBASE for eligible studies from inception. The 
search algorithms for these databases are presented in 
online supplementary file 2. We will search Metaregister, 
Physicians Data Query, www. controlled- trials. com/ rct, 
www. clinicaltrials. gov and www. cancer. gov/ clinicaltrials 
for ongoing studies. There will be no time or language 
restriction.
We will contact the corresponding author of any relevant 
ongoing trials for further information and unpublished 
data. In an attempt to identify any articles missed by the 
initial search, we will use the ‘related articles’ feature in 
MEDLINE. We will also hand search the references of the 
retrieved articles and meta-analyses. We will search confer-
ence proceedings and abstracts through ZETOC (http:// 
zetoc. mimas. ac. uk), and theses through WorldCat Disser-
tations. The selected conferences will include: British 
Society of Colposcopy and Cervical Pathology; Interna-
tional Federation of Cervical Pathology and Colposcopy; 
Annual Meeting of European Federation of Colposcopy; 
Annual Meeting of the American Society of Colposcopy 
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and Cervical Pathology. We will contact experts in the 
field, including directors of UK cancer and colposcopy 
registries, to identify further reports of studies. We will 
include both published and unpublished studies.
Study selection
We will download abstracts retrieved into a reference 
management software, Zotero. Then, two persons will 
independently review titles and abstracts retrieved by the 
search (level 1). At level 2, we will obtain the full text of 
all included articles and two reviewers will independently 
use the same inclusion criteria to determine eligibility. 
Disagreements at any level will be resolved via discussion 
with a third member of the review team.
data collection
Two reviewers will extract data independently using a stan-
dardised data collection form in Excel. Disagreements will 
be resolved through discussion. Information extracted 
will include study characteristics (such as author, publi-
cation year and study design), participants (such as age, 
CIN grade and smoking) and comparison group charac-
teristics, setting, inclusion/exclusion criteria, interven-
tion details, outcome measures and dropout rates. In 
RCTs, we will prefer arm-level data (number of events 
and sample size per intervention arm), but if these are 
missing, the study-level data will be used in the analysis, 
for example, reported ORs and a measure of their uncer-
tainty (eg, CI). In observational studies, we will extract 
estimates of treatment effects that are adjusted for the 
lack of randomisation, that is, after taking into account 
the impact of potential confounders, or, if these are 
missing, the reported unadjusted estimates, as well as the 
corresponding uncertainty measure.
risk of bias assessment
Results of the meta-analyses will be interpreted in light of 
risk of bias assessment of the included studies. Two inves-
tigators will independently assess the methodological 
quality/risk of bias of the studies that fulfil the eligibility 
criteria and differences will be resolved by discussion with 
a third investigator.
For RCTs, the risk of bias will be assessed using the tool30 
developed by Cochrane assessing the following domains: 
randomisation process, deviations from the intended 
interventions, missing outcome data, measurement of the 
outcome and selection of the reported result. The risk 
of bias in each domain, as well as the overall risk of bias, 
will be rated as ‘low risk’, ‘some concerns’ or ‘high risk’, 
after answering the signalling questions of each domain 
with ‘Yes’, ‘Potentially Yes’, ‘Potentially No’ or ‘No’. When 
inadequate detail s are reported in the study to be able to 
rate a risk of bias item, we will contact the study authors 
for additional information.
For non-randomised studies (NRS), we will use the 
ROBINS-I tool31 developed by the Cochrane collabora-
tion that facilitates the evaluation of the risk of bias by 
considering that each NRS is an attempt to mimic an 
RCT comparing the effects of the intervention or expo-
sure studied. During the review stage, we will evaluate 
the risk of bias in the following domains: confounding, 
selection of participants into the study, classification of 
interventions, deviations from intended interventions, 
missing data, measurement of outcomes and selection 
of the reported results. The confounding factors that we 
will evaluate are age, parity and smoking. Each ROBINS-I 
domain and the overall risk of bias will be assessed as 
‘low’, ‘moderate’, ‘serious’ or ‘critical’, after answering 
the signalling questions of each domain with Yes, Poten-
tially Yes, Potentially No or No.
Statistical synthesis
Characteristics of included studies and network
We will generate descriptive statistics for eligible studies 
and study population characteristics, describing the types 
of comparisons and important clinical or methodolog-
ical variables (such as publication year, study design and 
source of data). We will present the evidence in a network 
diagram per outcome. The total number of patients will 
be reflected in the size of the nodes, while the weight of 
each edge will be proportional to the number of studies 
per treatment comparison.
Pairwise meta-analyses
We will synthesise data to obtain summary ORs for dichot-
omous outcomes with a 95% CI in an inverse variance 
random-effects model assuming that the studies are esti-
mating different but related treatment effects. In each 
meta-analysis, we will estimate the between-study variance 
with the restricted maximum likelihood estimator32 33 
and its 95% CI using the Q-profile approach.34 We will 
assess between-study variance using the I2 statistic along 
a 95% CI.35 36 We will estimate each summary effect size 
and its 95% CI using the Hartung-Knapp-Sidik-Jonkman 
method32 37 38 to handle meta-analyses that include a small 
number of studies. All meta-analyses will be conducted in 
R39 using the metafor package.40
Network meta-analyses
Data synthesis
We will fit a random effects NMA model, taking into 
account the correlation induced by multiarm studies.41 
We will use a random-effects model, since we anticipate 
methodological and clinical heterogeneity across studies. 
We will assume a common between-study variance param-
eter for all comparisons in the network, so that treat-
ment comparisons informed by a single study can borrow 
strength from the remaining network.42 43 Clinically, this 
assumption is reasonable because all treatments included 
in the network are of the same nature. We will estimate 
the common between-study variance with the DerSimo-
nian and Laird method of moments approach.44
We expect that we will include several NRS in our dataset. 
In that case, we will employ the methods described by 
Efthimiou et al,45 that is, a ‘design-adjusted’, and a three-
level hierarchical NMA model. Using these methods, we 
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will incorporate the totality of available information, both 
randomised and observational, in a joint NMA. We will 
start by analysing the study-specific estimates from the 
NRS at face value. Then, in extensive sensitivity analyses, 
we will explore the impact of assigning different levels of 
credibility and subsequently down-weighting the NRS, 
according to experts’ opinion and the risk of bias as 
assessed in ROBINS-I.
For each treatment comparison, we will report the 
estimated OR, the 95% CI and the 95% prediction inter-
vals. We will also estimate the ranking probabilities for 
all treatments of being at each possible rank for each 
intervention. Thus, we will obtain a treatment hierarchy 
using the surface under the cumulative ranking curve 
(SUCRA) or P-scores and mean ranks.46 A rank-heat plot 
will be used to depict the SUCRA values or P-scores for all 
outcomes.47 48 All NMAs will be fit in R39 with the netmeta49 
and rjags50 package.
We will repeat our NMAs after grouping all excisional 
and all ablative techniques together; see groupings of 
treatments in figure 1.
Assessment of the transitivity assumption
NMA rests on the assumption of transitivity, that is, that 
effect modifiers have a similar distribution across treat-
ment comparisons in a network.24 51 52 In order to assess 
the plausibility of this assumption, we will summarise 
study and patient-level characteristics that are expected 
to influence relative treatment effects, for each pairwise 
comparison for which direct evidence is available in the 
network. In this NMA, the most important effect modi-
fiers are expected to be year of study, method of ascertain-
ment of exposure/outcome (hospital records, registries 
or interviews/questionnaires), age, parity, smoking and 
CIN grade. We will visually inspect the similarity of the 
identified studies in terms of these effect modifiers. We 
will investigate the inclusion and exclusion criteria of 
all studies, to make sure that patients, treatments and 
outcomes in the studies are sufficiently similar in all 
aspects that are expected to modify relative treatment 
effects.
Assessment of statistical inconsistency
Checking the network for inconsistency offers an addi-
tional way of assessing the validity of the transitivity 
assumption. In order to evaluate the presence of inconsis-
tency locally, we will separate the indirect from the direct 
evidence for each comparison and infer about their differ-
ences following the back-calculation method.53 We will 
also follow a global approach for assessing consistency in 
the network, by applying the design-by-treatment interac-
tion model.54 Simulations suggest that inconsistency tests 
have low power to detect true inconsistency.55 56 There-
fore, we will conceptually assess the transitivity assump-
tion (see previous paragraph) even in the absence of 
evidence for inconsistency. We will perform both local 
(back-calculation method) and global (design-by-treat-
ment interaction model) assessments in R39 using the 
netmeta package.49
When a network includes both randomised and 
non-randomised evidence, we will also explore differences 
between the different types of evidence, as discussed in 
Efthimiou et al.45 For each treatment comparison, there 
may be up to four different types of evidence: direct 
randomised, indirect randomised, direct non-randomised 
and indirect non-randomised. We will summarise all 
evidence by type, for each treatment comparison. If data 
permits, important discrepancies between these types will 
be further investigated, as they might indicate a breach 
of the transitivity assumption (eg, when randomised and 
non-randomised evidence are very different in terms of 
populations, interventions and so on), or the presence 
of important, unaccounted confounding in the non-ran-
domised evidence. If a source of disagreement is identi-
fied, it will be included in our analysis through network 
meta-regression models.23
Exploring heterogeneity and inconsistency: subgroup analyses, 
meta-regression and sensitivity analyses
We will assess the extent of statistical heterogeneity by 
inspecting the 95% prediction intervals and by comparing 
the estimated value of the between-study variance with 
the empirical distribution derived by Turner et al for 
dichotomous data.57 For the primary outcome, we will 
explore the following possible sources of heterogeneity 
and inconsistency: year of study, method of ascertainment 
of exposure/outcome (hospital records, registries or 
interviews/questionnaires), age, parity, smoking and CIN 
grade. If sufficient studies are available, the role of these 
variables will be explored by means of subgroup analyses 
(categorical characteristics) or network meta-regressions 
(continuous characteristics).
Reporting bias and small-study effects
In order to assess possible existence of small studies giving 
different effect estimates than larger studies, we will visu-
ally explore the funnel-plots for each treatment against 
the untreated group (using the relevant studies) when at 
least 10 studies inform the underling treatment compar-
ison. We will also assess for small-study effects using the 
comparison adjusted funnel plot58 and will conduct a 
network meta-regression using the study variance as a 
covariate.59 60
Assessment of the credibility of the evidence
We will evaluate the credibility of the evidence contrib-
uting to the network estimates in the primary outcome 
using CINeMA61 (http:// cinema. ispm. ch/). Two team 
members will determine the degree of confidence in 
the estimated NMA results by assessing the six CINeMA 
domains: within-study bias (ie, risk of bias in the included 
studies), across-study bias (ie, publication and reporting 
bias), indirectness, imprecision, heterogeneity and inco-
herence (ie, differences between direct and indirect 
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evidence).61 Each network summary estimate will initially 
be judged as high quality, but it will be downgraded if 
this is judged appropriate according to the six domains. 
Judgements within each domain will be summarised 
for each NMA relative treatment effect as: very low, low, 
moderate or high.
Patient and public involvement
We have discussed the project with Jo’s Cervical Cancer 
Trust (a UK charity who supports patients affected by 
cervical preinvasive or invasive cervical disease and 
campaigns for excellence in cervical cancer treatment 
and prevention).
Two patient representatives through Jo’s Trust with 
personal experience of cervical disease have assisted us in 
the design of the study and the development of research 
questions. We aim to recruit more patients through Jo’s 
Voice, who will help us understand the key priorities from 
patients’ perspective, produce lay summaries and dissem-
inate the results to the wider public.
Ethics and dissemination
This review does not require ethical approval. We identi-
fied four groups of potential stakeholders (academic bene-
ficiaries; health-related agencies and decision-makers; 
medical practitioners; patients and public) and specific 
action items to effectively target them. We will publish 
papers in influential open access journals and we will 
present data at high-profile conferences. We will make the 
datasets available to the wider research community. We 
will organise a workshop with key stakeholders. We will 
develop information sheets and briefings, highlighting 
the key findings and circulate newsletters. We will engage 
the press with presentations and social media interviews 
and we will work closely with Jo’s Trust charity that plays 
an important role in educating patient communities.
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